124 related articles for article (PubMed ID: 9713297)
1. Dose intensification of epidoxorubicin and cyclophosphamide in metastatic breast cancer: a randomised study with two schedules of granulocyte-macrophage colony stimulating factor.
Stöger H; Samonigg H; Krainer M; Ploszczynski M; Nirnberger G; Maca S; Hehenwarter W; Wirth M; Schüller J; Vavra N; Scheithauer W; Kornek G; Stierer M; Zielinski CC
Eur J Cancer; 1998 Mar; 34(4):482-8. PubMed ID: 9713297
[TBL] [Abstract][Full Text] [Related]
2. Granulocyte-macrophage colony-stimulating factor (GM-CSF) allows acceleration and dose intensity increase of CEF chemotherapy: a randomised study in patients with advanced breast cancer.
Ardizzoni A; Venturini M; Sertoli MR; Giannessi PG; Brema F; Danova M; Testore F; Mariani GL; Pennucci MC; Queirolo P
Br J Cancer; 1994 Feb; 69(2):385-91. PubMed ID: 8297739
[TBL] [Abstract][Full Text] [Related]
3. Dose-intensity of a four-drug chemotherapy regimen with or without recombinant human granulocyte-macrophage colony-stimulating factor in extensive-stage small-cell lung cancer: a multicenter randomized phase III study.
Pujol JL; Douillard JY; Rivière A; Quoix E; Lagrange JL; Berthaud P; Bardonnet-Comte M; Polin V; Gautier V; Milleron B; Chomy F; Chomy P; Spaeth D; Le Chevalier T
J Clin Oncol; 1997 May; 15(5):2082-9. PubMed ID: 9164221
[TBL] [Abstract][Full Text] [Related]
4. The impact of schedule on acute toxicity and dose-intensity of high-dose chemotherapy with epirubicin and cyclophosphamide plus colony stimulating factors in advanced breast cancer.
De Placido S; Lauria R; Carlomagno C; Perrone F; De Laurentiis M; Gallo C; Martignetti A; Bellelli T; Limite G; Petrella G; Bianco AR
Int J Oncol; 1999 Aug; 15(2):339-46. PubMed ID: 10402245
[TBL] [Abstract][Full Text] [Related]
5. Accelerated chemotherapy with high-dose epirubicin and cyclophosphamide plus r-met-HUG-CSF in locally advanced and metastatic breast cancer.
Scinto AF; Ferraresi V; Campioni N; Tonachella R; Piarulli L; Sacchi I; Giannarelli D; Cognetti F
Ann Oncol; 1995 Sep; 6(7):665-71. PubMed ID: 8664187
[TBL] [Abstract][Full Text] [Related]
6. A dose intensity study of FLAC (5-fluorouracil, leucovorin, doxorubicin, cyclophosphamide) chemotherapy and Escherichia coli-derived granulocyte-macrophage colony-stimulating factor (GM-CSF) in advanced breast cancer patients.
O'Shaughnessy JA; Denicoff AM; Venzon DJ; Danforth D; Pierce LJ; Frame JN; Bastian A; Ghosh B; Goldspiel B; Miller L
Ann Oncol; 1994 Oct; 5(8):709-16. PubMed ID: 7826903
[TBL] [Abstract][Full Text] [Related]
7. Erythropoietin and granulocyte-macrophage colony-stimulating factor allow acceleration and dose escalation of cyclophosphamide/epidoxorubicin/5-fluorouracil chemotherapy: a dose-finding study in patients with advanced breast cancer.
Venturini M; Del Mastro L; Testore F; Danova M; Garrone O; Lanfranco C; Latini F; Sertoli MR; Lionetto R; Queirolo P; Ardizzoni A; Rosso R
Cancer Chemother Pharmacol; 1996; 38(6):487-94. PubMed ID: 8823488
[TBL] [Abstract][Full Text] [Related]
8. Comparative study of dose escalation versus interval reduction to obtain dose-intensification of epirubicin and cyclophosphamide with granulocyte colony-stimulating factor in advanced breast cancer.
Lalisang RI; Wils JA; Nortier HW; Burghouts JT; Hupperets PS; Erdkamp FL; Schouten HC; Blijham GH
J Clin Oncol; 1997 Apr; 15(4):1367-76. PubMed ID: 9193328
[TBL] [Abstract][Full Text] [Related]
9. A randomised phase II study of conventional versus accelerated infusional chemotherapy with granulocyte colony-stimulating factor support in advanced breast cancer.
De Boer RH; Eisen TG; Ellis PA; Johnston SR; Walsh G; Ashley S; Smith IE
Ann Oncol; 2002 Jun; 13(6):889-94. PubMed ID: 12123334
[TBL] [Abstract][Full Text] [Related]
10. Accelerated-intensified cyclophosphamide, epirubicin, and fluorouracil (CEF) compared with standard CEF in metastatic breast cancer patients: results of a multicenter, randomized phase III study of the Italian Gruppo Oncologico Nord-Ouest-Mammella Inter Gruppo Group.
Del Mastro L; Venturini M; Lionetto R; Carnino F; Guarneri D; Gallo L; Contu A; Pronzato P; Vesentini L; Bergaglio M; Comis S; Rosso R
J Clin Oncol; 2001 Apr; 19(8):2213-21. PubMed ID: 11304774
[TBL] [Abstract][Full Text] [Related]
11. Effect of granulocyte-macrophage colony-stimulating factor (GM-CSF) on hematologic toxicity induced by high-dose chemotherapy in patients with metastatic breast cancer.
Hansen F; Stenbygaard L; Skovsgaard T
Acta Oncol; 1995; 34(7):919-24. PubMed ID: 7492381
[TBL] [Abstract][Full Text] [Related]
12. A phase I study of sequential versus concurrent interleukin-3 and granulocyte-macrophage colony-stimulating factor in advanced breast cancer patients treated with FLAC (5-fluorouracil, leucovorin, doxorubicin, cyclophosphamide) chemotherapy.
O'Shaughnessy JA; Venzon DJ; Gossard M; Noone MH; Denicoff A; Tolcher A; Danforth D; Jacobson J; Keegan P; Miller L; Chow C; Goldspiel B; Cowan KH
Blood; 1995 Oct; 86(8):2913-21. PubMed ID: 7579383
[TBL] [Abstract][Full Text] [Related]
13. Impact of five prophylactic filgrastim schedules on hematologic toxicity in early breast cancer patients treated with epirubicin and cyclophosphamide.
Papaldo P; Lopez M; Marolla P; Cortesi E; Antimi M; Terzoli E; Vici P; Barone C; Ferretti G; Di Cosimo S; Carlini P; Nisticò C; Conti F; Di Lauro L; Botti C; Di Filippo F; Fabi A; Giannarelli D; Calabresi F
J Clin Oncol; 2005 Oct; 23(28):6908-18. PubMed ID: 16129844
[TBL] [Abstract][Full Text] [Related]
14. Comparative effects of three cytokine regimens after high-dose cyclophosphamide: granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor (GM-CSF), and sequential interleukin-3 and GM-CSF.
Ballestrero A; Ferrando F; Garuti A; Basta P; Gonella R; Stura P; Mela GS; Sessarego M; Gobbi M; Patrone F
J Clin Oncol; 1999 Apr; 17(4):1296. PubMed ID: 10561192
[TBL] [Abstract][Full Text] [Related]
15. Phase I trial of infusional cyclophosphamide, doxorubicin, and etoposide plus granulocyte-macrophage colony stimulating factor (GM-CSF) in non-Hodgkin's lymphoma.
Sparano JA; Negassa A; Lansigan E; Locke R; De Silva CR; Wiernik PH
Med Oncol; 2005; 22(3):257-67. PubMed ID: 16110137
[TBL] [Abstract][Full Text] [Related]
16. Granulocyte-macrophage colony-stimulating factor increases dose intensity of chemotherapy in small cell lung cancer. Relationship between clinical results, peripheral blood cell modifications, and bone marrow kinetics.
Paccagnella A; Favaretto A; Riccardi A; Danova M; Ghiotto C; Giordano M; Pappagallo G; Comis S; Panozzo M; Chieco-Bianchi L
Cancer; 1993 Aug; 72(3):697-706. PubMed ID: 8392903
[TBL] [Abstract][Full Text] [Related]
17. Effects of recombinant human granulocyte-macrophage colony-stimulating factor on myelosuppression induced by multiple cycles of high-dose chemotherapy in patients with advanced breast cancer.
Hoekman K; Wagstaff J; van Groeningen CJ; Vermorken JB; Boven E; Pinedo HM
J Natl Cancer Inst; 1991 Nov; 83(21):1546-53. PubMed ID: 1960751
[TBL] [Abstract][Full Text] [Related]
18. Short-term administration of granulocyte-macrophage colony stimulating factor decreases hematopoietic toxicity of cytostatic drugs.
Aglietta M; Monzeglio C; Pasquino P; Carnino F; Stern AC; Gavosto F
Cancer; 1993 Nov; 72(10):2970-3. PubMed ID: 8221563
[TBL] [Abstract][Full Text] [Related]
19. Addition of either lonidamine or granulocyte colony-stimulating factor does not improve survival in early breast cancer patients treated with high-dose epirubicin and cyclophosphamide.
Papaldo P; Lopez M; Cortesi E; Cammilluzzi E; Antimi M; Terzoli E; Lepidini G; Vici P; Barone C; Ferretti G; Di Cosimo S; Nistico C; Carlini P; Conti F; Di Lauro L; Botti C; Vitucci C; Fabi A; Giannarelli D; Marolla P
J Clin Oncol; 2003 Sep; 21(18):3462-8. PubMed ID: 12972521
[TBL] [Abstract][Full Text] [Related]
20. Randomized double-blind prospective trial to evaluate the effects of sargramostim versus placebo in a moderate-dose fluorouracil, doxorubicin, and cyclophosphamide adjuvant chemotherapy program for stage II and III breast cancer.
Jones SE; Schottstaedt MW; Duncan LA; Kirby RL; Good RH; Mennel RG; George TK; Snyder DA; Watkins DL; Denham CA; Hoyes FA; Rubin AS
J Clin Oncol; 1996 Nov; 14(11):2976-83. PubMed ID: 8918495
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
